DrugPatentWatch Database Preview
Lisinopril - Generic Drug Details
» See Plans and Pricing
What are the generic sources for lisinopril and what is the scope of patent protection?
Lisinopril
is the generic ingredient in four branded drugs marketed by Azurity, Accord Hlthcare, Ascent Pharms Inc, Atlantide, Aurobindo, Chartwell Rx, Corepharma, Heritage Pharma, Hikma Intl Pharms, Invagen Pharms, Lupin, Mylan, Pharmgen, Prinston Inc, Sun Pharm Inds Ltd, Teva, Watson Labs, Yiling, Merck, and Almatica, and is included in twenty-one NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lisinopril has seven patent family members in seven countries.
There are twenty-one drug master file entries for lisinopril. Forty-three suppliers are listed for this compound.
Summary for lisinopril
| International Patents: | 7 |
| US Patents: | 6 |
| Tradenames: | 4 |
| Applicants: | 20 |
| NDAs: | 21 |
| Drug Master File Entries: | 21 |
| Suppliers / Packagers: | 43 |
| Bulk Api Vendors: | 73 |
| Clinical Trials: | 103 |
| Patent Applications: | 6,868 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for lisinopril |
| Drug Sales Revenues: | Drug sales revenues for lisinopril |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for lisinopril |
| What excipients (inactive ingredients) are in lisinopril? | lisinopril excipients list |
| DailyMed Link: | lisinopril at DailyMed |
Recent Clinical Trials for lisinopril
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fondazione Schena | Phase 4 |
| University of Bari | Phase 4 |
| Lupus Research Alliance | Phase 2 |
Pharmacology for lisinopril
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Medical Subject Heading (MeSH) Categories for lisinopril
Paragraph IV (Patent) Challenges for LISINOPRIL
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| QBRELIS | SOLUTION;ORAL | lisinopril | 208401 | 2019-10-24 |
US Patents and Regulatory Information for lisinopril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prinston Inc | LISINOPRIL | lisinopril | TABLET;ORAL | 075743-002 | Jul 1, 2002 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Teva | LISINOPRIL | lisinopril | TABLET;ORAL | 075783-006 | Jul 1, 2002 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Almatica | ZESTRIL | lisinopril | TABLET;ORAL | 019777-002 | May 19, 1988 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Chartwell Rx | LISINOPRIL | lisinopril | TABLET;ORAL | 075994-006 | Jul 1, 2002 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for lisinopril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Almatica | ZESTRIL | lisinopril | TABLET;ORAL | 019777-002 | May 19, 1988 | Start Trial | Start Trial |
| Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-006 | Jan 28, 1994 | Start Trial | Start Trial |
| Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-003 | Dec 29, 1987 | Start Trial | Start Trial |
| Almatica | ZESTRIL | lisinopril | TABLET;ORAL | 019777-005 | Apr 29, 1993 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for lisinopril
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2018533583 | Start Trial |
| China | 108472252 | Start Trial |
| Canada | 3003274 | Start Trial |
| South Korea | 20180069907 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
